RECRUITING

Video Education With Result Dependent dIsclosure

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.

Official Title

Video Education With Result Dependent dIsclosure

Quick Facts

Study Start:2022-08-04
Study Completion:2026-09-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05225428

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age ≥ 18 years
  2. * Current or prior diagnosis of breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer, renal cancer, melanoma, or sarcoma
  3. * Ability to understand spoken or written English or Spanish in a healthcare context
  4. * Ability to understand and the willingness to sign a written informed consent document
  5. * Black or Latinx (qualitative assessment study only)
  1. * Prior cancer genetic testing
  2. * Prior germline genetic testing
  3. * Active hematologic malignancy (e.g. chronic lymphocytic leukemia)
  4. * Currently pregnant
  5. * Currently incarcerated

Contacts and Locations

Study Contact

Huma Q. Rana, MD. MPH
CONTACT
617) 632-6292
humaQ_rana@dfci.harvard.edu

Principal Investigator

Huma Q. Rana, MD., MPH
PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute

Study Locations (Sites)

Dana Farber Cancer Institute
Boston, Massachusetts, 02115
United States

Collaborators and Investigators

Sponsor: Dana-Farber Cancer Institute

  • Huma Q. Rana, MD., MPH, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-08-04
Study Completion Date2026-09-01

Study Record Updates

Study Start Date2022-08-04
Study Completion Date2026-09-01

Terms related to this study

Keywords Provided by Researchers

  • Genetic Testing
  • Breast Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Renal Cancer
  • Melanoma
  • Sarcoma

Additional Relevant MeSH Terms

  • Genetic Testing
  • Breast Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Renal Cancer
  • Melanoma
  • Sarcoma